Table 5. Studies examining the expression and clinical role of survivin in ovarian cancer.
|
Relation with
|
Correlation with poor survival
|
Correlation with poor response to chemotherapy
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author (year) | Prevalent expression in | No. | Method (section) | Antibody | Positivity expressed on | Cutoff | % positive cases | p53 | bcl-2 | Uni | Multi | Uni | Multi |
| Yoshida (2001) | Cytoplasm | 32a | IC Paraffin | Surv11A | ND | Weighted score >5b | 18.7 | — | — | Yes | — | — | — |
| Takai (2002) | Nucleus | 26 | IC Cryostat | FL-142 | ND | >60% positive cells | 34.6 | — | — | Yes | — | — | — |
| Sui (2002) | Nucleus | 47 | IC Paraffin | Surv11A | ND | >50% positive cells | 51.1 | — | — | Yes | — | — | — |
| Zaffaroni (2002) | Cytoplasm | 124 | IC Paraffin | Ab469 | Cytoplasm and/or Nucleus | >30% positive cells | 72.5 | No | — | — | — | Direct | Direct |
| Cohen (2003) | Nucleus | 49 | IC Paraffin | FL-142 | Cytoplasm and/or Nucleus | ND | 74.0 | Yes | No | No | — | — | — |
| Current study | Cytoplasm | 110 | IC Paraffin | Ab469 | Cytoplasm | >20% cells (score>1) | 84.5 | No | No | No | — | No | — |
| Nucleus | >5% cells (score⩾1) | 29.1 | No | No | No | — | No | — | |||||
Uni=univariate analysis; Multi=multivariate analysis; IC=immunohistochemistry; ND=not defined.
a
Including 16 clear cell and 16 serous adenocarcinomas.
b
Weighted score obtained by multiplying the percentage of positive cells and intensity of staining.